Genmab A/s (NASDAQ: GMAB)
Genmab A/s Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Genmab A/s Company Info
Genmab has developed multiple technologies for creating antibody-based drugs, generates revenue through royalties on partner-produced drugs, and has a robust pipeline to feed future growth.
News & Analysis
AbbVie Signs $3.9 Billion Oncology Deal with Genmab
The partners will develop and hopefully commercialize up to seven new cancer drugs.
Are There Good Investments Among 2019's Biotech IPOs?
Investing in biotechs is inherently risky. IPOs are too. What does the stock performance of 2019’s biotech IPO class look like so far?
Valuation
Earnings Transcripts
Genmab A/S (GMAB) Q2 2022 Earnings Call Transcript
GMAB earnings call for the period ending June 30, 2022.
Genmab A/S (GMAB) Q1 2022 Earnings Call Transcript
GMAB earnings call for the period ending March 31, 2022.
Genmab A/S (GMAB) Q4 2021 Earnings Call Transcript
GMAB earnings call for the period ending December 31, 2021.
Genmab A/S (GMAB) Q3 2021 Earnings Call Transcript
GMAB earnings call for the period ending September 30, 2021.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.